Bio-Rad Laboratories, Inc. BIO.B

365.08 0.00 0.00% as of 24 Sep
Market cap
$10.3B
P/E
43.8×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
2,068.17 2,160.15 2,289.42 2,311.66 2,545.63 2,922.55 2,802.20 2,671.20 2,566.50 2,583.20
Revenue Growth
2.41% 4.45% 5.98% 0.97% 10.12% 14.81% (4.12%) (4.67%) (3.92%) 0.65%
Cost of Revenue
929.74 972.45 1,066.26 1,054.66 1,107.74 1,284.45 1,234.90 1,244.30 1,187.60 1,243.30
Gross Profit
1,138.43 1,187.70 1,223.15 1,257.00 1,437.89 1,638.10 1,567.30 1,426.90 1,378.90 1,339.90
R&D Expenses
205.71 250.16 199.20 202.71 217.76 260.64 256.89 247.43 — —
SG&A Expenses
814.70 806.79 834.78 824.63 798.80 877.12 827.80 841.70 814.00 844.30
Operating Income
55.72 119.25 (103.34) 229.66 421.33 500.34 482.60 337.80 269.00 47.20
Non-operating Income/Expense
(14.16) (21.44) 616.00 2,031.42 4,496.68 4,948.72 (5,186.80) (1,187.90) (2,611.50) 948.30
Non-operating Interest Expenses
23.38 23.01 23.96 23.42 21.86 1.55 38.10 49.40 48.90 49.00
EBT
41.56 97.81 512.66 2,261.08 4,918.01 5,449.06 (4,704.20) (850.10) (2,342.50) 995.50
Income Tax Provision
15.56 (24.44) 147.05 502.41 1,103.78 1,194.80 (1,076.70) (212.80) (498.30) 235.60
Income after Tax
26.00 122.25 365.61 1,758.68 3,814.23 4,254.26 (3,627.50) (637.30) (1,844.20) 759.90
Net Income Common
26.00 122.25 365.61 1,758.68 3,814.23 4,254.26 (3,627.50) (637.30) (1,844.20) 759.90
EPS (Basic)
0.96 3.87 12.10 58.93 127.86 142.33 (121.79) (21.82) (65.36) 27.87
EPS (Diluted)
0.95 3.82 11.94 58.27 126.20 140.56 (121.79) (21.82) (65.36) 27.85
Shares (Basic, Weighted)
29.44 29.66 29.84 29.84 29.77 29.83 29.79 29.21 28.21 27.26
Shares (Diluted, Weighted)
29.65 30.03 30.23 30.18 30.16 30.21 29.79 29.21 28.21 27.28
Gross Margin
55.05% 54.98% 53.43% 54.38% 56.48% 56.05% 55.93% 53.42% 53.73% 51.87%
EBIT Margin
2.69% 5.52% (4.51%) 9.93% 16.55% 17.12% 17.22% 12.65% 10.48% 1.83%
EBT margin
2.01% 4.53% 22.39% 97.81% 193.19% 186.45% (167.88%) (31.82%) (91.27%) 38.54%
Net Profit Margin
1.26% 5.66% 15.97% 76.08% 149.83% 145.57% (129.45%) (23.86%) (71.86%) 29.42%
Free Cash Flow Margin
3.62% (0.50%) 6.99% 15.93% 18.85% 18.33% 2.87% 8.18% 11.29% 14.51%
EBITDA
55.72 119.25 (103.34) 229.66 421.33 500.34 482.60 337.80 269.00 47.20
EBIT
55.72 119.25 (103.34) 229.66 421.33 500.34 482.60 337.80 269.00 47.20
Income from Continuous Operations
26.00 122.25 365.61 1,758.68 3,814.23 4,254.26 (3,627.50) (637.30) (1,844.20) 759.90
Consolidated Net Income/Loss
26.00 122.25 365.61 1,758.68 3,814.23 4,254.26 (3,627.50) (637.30) (1,844.20) 759.90
EPS (Basic, from Continuous Ops)
0.88 4.12 12.25 58.93 128.13 142.61 (121.79) (21.82) (65.36) 27.87
EPS (Basic, Consolidated)
0.88 4.12 12.25 58.93 128.13 142.61 (121.79) (21.82) (65.36) 27.87
EPS (Diluted, from Cont. Ops)
0.88 4.07 12.10 58.27 126.47 140.83 (121.79) (21.82) (65.36) 27.85
Shares (Diluted, Average)
29.65 30.03 30.23 30.18 30.16 30.21 29.79 29.21 28.21 27.28
EPS (Diluted, Consolidated)
0.88 4.07 12.10 58.27 126.47 140.83 (121.79) (21.82) (65.36) 27.85
EBITDA Margin
2.69% 5.52% (4.51%) 9.93% 16.55% 17.12% 17.22% 12.65% 10.48% 1.83%
Operating Cash Flow Margin
10.45% 4.82% 12.47% 19.81% 22.98% 22.91% 6.94% 14.03% 17.74% 20.60%

Fold the line items

In millions of $ except per-share values · columns are period end dates